Home › Funds › TRILLIUM ASSET MANAGEMENT, LLC › VRTX

TRILLIUM ASSET MANAGEMENT, LLC position in VRTX

VERTEX PHARMACEUTICALS INC · Health Care

TRILLIUM ASSET MANAGEMENT, LLC reported holding 58,144 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$30.4M, representing 0.95% of its reported portfolio and ranking #24 among its reported holdings. TRILLIUM ASSET MANAGEMENT, LLC has disclosed VRTX holdings in 10 of the last 10 reported quarters, going back to Q2 2024.

Latest position (Q3 2026)58.14K sh
Reported value held$30.40M
Portfolio Weight0.95%
First reportedQ2 2024
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How TRILLIUM ASSET MANAGEMENT, LLC's VRTX position evolved

TRILLIUM ASSET MANAGEMENT, LLC first disclosed a stake in VRTX in Q2 2024 at 17,579 shares (US$8.2M). The position peaked in Q3 2026 at 58,144 shares, worth US$30.4M. Across 10 filings, TRILLIUM ASSET MANAGEMENT, LLC increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 58,144 shares valued at US$30.4M — a reduction of -1,961 shares quarter over quarter.. Notable position changes include a 229% increase in Q1 2025 (shares fell 8% over the following quarter), a 59% increase in Q1 2026 (shares rose 11% over the following quarter), a 40% trim in Q2 2026 (shares rose 5% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2024 17.58K $8.24M New
Q3 2024 18.08K $8.41M Add
Q4 2024 16.96K $6.83M Reduce
Q1 2025 55.82K $27.06M Add
Q2 2025 61.47K $27.37M Add
Q3 2025 68.39K $26.78M Add
Q4 2025 62.69K $28.57M Reduce
Q1 2026 99.76K $28.09M Add
Q2 2026 60.10K $29.86M Reduce
Q3 2026 58.14K $30.40M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRTX and 13F data

VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 32 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$13.58B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRTX

All VRTX fund holders →

FAQ

How long has TRILLIUM ASSET MANAGEMENT, LLC held VRTX?

TRILLIUM ASSET MANAGEMENT, LLC has disclosed VRTX holdings in 10 of the last 10 reported quarters, going back to Q2 2024.

What is TRILLIUM ASSET MANAGEMENT, LLC's current position in VRTX?

As of Q3 2026, TRILLIUM ASSET MANAGEMENT, LLC holds 58.14K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $30.40M, representing 0.95% of its reported portfolio and ranking #24.

Has TRILLIUM ASSET MANAGEMENT, LLC been buying or selling VRTX?

In the latest 13F filing (Q3 2026), TRILLIUM ASSET MANAGEMENT, LLC reduced its position in VRTX. The position peaked in Q3 2026 at 58.14K shares.

Which other funds hold VRTX?

Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 32 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.